Tagged with CMO

Mexico Ricardo Spínola, CEO at Farmapiel, explains his clear vision for the company and showcases the added value of Farmapiel’s product offering for both patients and healthcare professionals. Mr. Spínola you have more than 16 years of experience in top management positions for leading pharmaceutical companies and private hospitals. Nevertheless, in…

Switzerland Gabriel Haering, CEO of API manufacturer Cerbios, highlights the importance of “Swiss-ness” to the company’s brand, their attentiveness to diversification and scaling the value chain, and the future prospects for Swiss CMOs. Cerbios is renowned for its expertise in the process development and contract manufacturing of Active Pharmaceutical Ingredients (APIs) and…

Switzerland The managing director of CordenPharma Switzerland elaborates on the role the Swiss facility plays within CordenPharma. He furthermore highlights how the company is tailoring their service offering to cater to the needs of multi-national companies, mid-sized companies as well as start-ups. You worked in various positions in Lonza for 27…

Switzerland Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by working instead with a competent CMO – a form of insurance as explained by Siegfried CEO Rudolf Hanko.   The CMO sector has grown faster than the pharma…

CMO Marian Gono, COO, and Marian Takac, VP Sales and Marketing, of Hameln rds discuss the scope of the company’s operations in Slovakia, the key milestone of attaining FDA approval just three years after setting up the facility, and the challenges and opportunities of being based in Slovakia. Could you first…

Pharma Socorro España Lomelí, executive director of Mexico’s National Association of Drug Manufacturers (ANAFAM), details her strategic priorities with regards to the promotion of the industry’s export strategy, the implementation of world-class manufacturing norms, the development of biosimilars and API manufacturing, as well as recognizing the pharmaceutical sector as a strategic…

Pharma Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation and complying with regulatory standards. Given its more than 100-year legacy in the country, how has the pharmaceutical industry supported…

Pharma János Burovincz, Managing Director of Patent, shares his insights on building a company from scratch, the importance of maintaining a diverse portfolio that can quickly adapt to market needs as well as his priorities going forward to continue growing the company’s footprint in Hungary. He also discusses the company’s strong…

Pharma The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also discuss the complexities of the Hungarian healthcare and pharmaceutical market and give an overview of their past challenges and current…

Pharma Soneas MD Jozsef Repasi discusses the shift back towards Central and Eastern Europe for contract manufacturing services, the company’s growth since separating from Ubichem, and his ambitions for Soneas to become a fully integrated, end-to-end service provider. As an introduction for our readers, can you please shed some insight into…

Pharma Sebastien Aguettant, president of the French Association of Pharmaceutical Contract Manufacturers (SPIS) and president of leading French CMO Delpharm, discusses the evolutions and growing significance of contract manufacturing, how CMO pharma manufacturing has only just begun, and how Delpharm with its ten sites in France is a reliable partner of…

Pharma Bernard Fraisse of Fareva, France’s leading CMO, discusses growth, international expansion, loyalty to France, dedication to clients, and commitment to providing high quality products. Many have predicted that pharma manufacturing in France will soon die out, but instead we have seen a shift from manufacturing of large pharmaceutical groups to…